Twinrix

From Wikipedia, the free encyclopedia - View original article

 
Jump to: navigation, search
Twinrix GlaxoSmithKline - i-hepA & r-hepB-S-Ag - doos Terumo-naald spuiten.JPG

Twinrix is a vaccine against hepatitis A and hepatitis B, manufactured by GlaxoSmithKline. Twinrix is administered over three doses.

The name was created because it is a mixture of two earlier vaccines — Havrix, an inactivated-virus Hepatitis A vaccine, and ENGERIX-B, a recombinant Hepatitis B vaccine. TWINRIX, HAVRIX and ENGERIX-B are registered trademarks of GlaxoSmithKline; if the same vaccine is available from others, it will have another name.

Twinrix first entered the market in early 1997.

Administration schedule[edit]

Twinrix can be administered on the same schedule as monovalent Hepatitis B vaccine: at 0- 1- and 6- months. In some circumstances, an accelerated dosing schedule of 0- 7- and 21-to 30- days followed by a booster at 12 months can be used and is believed to have similar efficacy as the traditional schedule.[1] It is approved for those 18 years old and older.[citation needed]

Efficacy[edit]

The CDC reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose:[2]

A: 93.8%, 98.8%, 99.9%
B: 30.8%, 78.2%, 98.5%

GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.[3]

See also[edit]

References[edit]

  1. ^ http://us.gsk.com/products/assets/us_twinrix.pdf
  2. ^ "FDA approval for a combined hepatitis A and B vaccine". MMWR Morb. Mortal. Wkly. Rep. 50 (37): 806–7. September 2001. PMID 11785573. 
  3. ^ Twinrix Adult Vaccine, SPC from the eMC

External links[edit]